Cosmo Pharmaceuticals Appoints New Chief Financial Officer

Rhea-AI Summary

Cosmo Pharmaceuticals has appointed Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Sigalova, who previously served as Vice President of Commercial Finance at Moderna, brings extensive experience in managing multibillion-dollar revenue streams and developing financial infrastructure. She succeeds Niall Donnelly, who will transition to a new role as EVP - Corporate Governance & Chief Sustainability Officer.

In her new position, Donnelly will focus on strengthening Cosmo's corporate governance framework and advancing ESG initiatives, including carbon footprint reduction. He will remain an executive member of the Board of Directors. CEO Giovanni Di Napoli expressed confidence that Sigalova's expertise will guide Cosmo's financial strategy and support its global expansion, while Donnelly's new role will reinforce the company's commitment to responsible growth and long-term value.

Positive

• Appointment of experienced CFO with background in managing multibillion-dollar revenue streams
• Former CFO transitioning to focus on strengthening corporate governance and ESG initiatives
• Strategic move aligned with global expansion plans

Negative

• None.

Ad hoc announcement pursuant to Art. 53 LR

Dublin, Ireland--(Newsfile Corp. - October 11, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is delighted to announce the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016.

Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna’s rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency.

Niall will transition to a strategic new role as EVP – Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo’s corporate governance framework and driving the Company’s mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall’s leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company’s long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo.

Giovanni Di Napoli, CEO of Cosmo, commented: “Svetlana’s appointment marks a pivotal step in Cosmo’s global expansion strategy. With her extensive experience in fast-growing, global organizations, she will be an invaluable asset in guiding our financial strategy, driving performance, and supporting our mission to enhance our presence in international markets. We are excited to have her expertise as we take Cosmo to the next level.”

Giovanni added: “At the same time, we want to extend our heartfelt gratitude to Niall for his outstanding service as CFO over the past eight years. Niall has been instrumental in shaping Cosmo’s financial foundation, and we are thrilled that he will continue to bring his vast experience and strategic insight to our corporate governance and ESG efforts. His leadership in establishing strong governance frameworks and driving sustainability initiatives will be key in reinforcing the commitment of our Company to responsible growth and long-term value.”

Svetlana Sigalova stated: “I am truly honored to join Cosmo’s dynamic team and excited to work alongside the Management Team and employees to support the company’s ambitious growth plans. It is a privilege to contribute to such an innovative organization with solid revenue drivers and promising R&D projects. I look forward to leveraging my experience to help drive Cosmo’s financial excellence and global expansion.”

About Cosmo
Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. The current growth drivers, including the state-of-the-art GI Genius™ intelligent endoscopy system that enhances polyp detection rates during colonoscopy and the prescription drug Winlevi® to treat acne are generating substantial revenue streams. The Company’s proprietary MMX® technology enables targeted delivery of active ingredients in the colon and is a cornerstone of its product development. Cosmo also has a robust clinical development pipeline, which includes Breezula® for the treatment of androgenetic alopecia. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company currently has approximately 300 employees, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.

Upcoming Calendar of Events
UBS Global Healthcare Conference, California             November 11-14, 2024
Jefferies London Healthcare Conference, London        November 19-21, 2024

For further information, please contact
Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
hwinchester@cosmopharma.com

Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.

Attachments

241011_Cosmo Pharma_Media Release_New CFO_EN

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226361

FAQ

Who is the new CFO of Cosmo Pharmaceuticals (CMOPF)?

Svetlana Sigalova has been appointed as the new Chief Financial Officer of Cosmo Pharmaceuticals, effective November 11, 2024.

What is Svetlana Sigalova's background before joining Cosmo Pharmaceuticals (CMOPF)?

Svetlana Sigalova previously served as Vice President of Commercial Finance at Moderna, where she led financial operations for over $6 billion in global sales. She also held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals.

What new role will former CFO Niall Donnelly take at Cosmo Pharmaceuticals (CMOPF)?

Niall Donnelly will transition to the role of EVP - Corporate Governance & Chief Sustainability Officer, focusing on strengthening Cosmo's corporate governance framework and driving ESG initiatives.

When will Svetlana Sigalova start as CFO of Cosmo Pharmaceuticals (CMOPF)?

Svetlana Sigalova will start her role as Chief Financial Officer of Cosmo Pharmaceuticals on November 11, 2024.